Cas:896046-85-8 1-[(3-fluorophenyl)methyl]piperidine-3-carboxylic acid manufacturer & supplier

Chemical Name:1-[(3-fluorophenyl)methyl]piperidine-3-carboxylic acid

CAS.NO:896046-85-8

Synonyms:1-[(3-fluorophenyl)methyl]piperidine-3-carboxylic acid

Molecular Formula:C₁₃H₁₆FNO₂

Molecular Weight:237.27000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.234

Index of Refraction:

PSA:40.54000

Exact Mass:237.11700

LogP:2.06020

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-[(3-fluorophenyl)methyl]piperidine-3-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-[(3-fluorophenyl)methyl]piperidine-3-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-[(3-fluorophenyl)methyl]piperidine-3-carboxylic acid Use and application,1-[(3-fluorophenyl)methyl]piperidine-3-carboxylic acid technical grade,usp/ep/jp grade.

Related News: Less than three weeks after unveiling the construction of a new fill-finish facility in Morocco, the Sweden-based company announced it was undergoing construction of another fill-finish plant in India. 2-{2-[(Adamantane-1-carbonyl)-amino]-4-trifluoromethyl-phenyl}-propionic acid methyl ester manufacturers One of the main benefits of biocatalysis is that it increases conversion efficiency for significantly higher yields with fewer by-products, equating to faster and more cost-effective production. 7-o-Hydroxyphenyl-5,6-dihydrothiopyrano(2,3-d)thiazolidine-2-thione-5,6-dimethylcarboxylate suppliers In taking control of Vanamali, Wavelength will double the firm’s production capacity and add more than 10 key regulatory starting materials and drug intermediates for Wavelength’s own strategic APIs and API CDMO customers, a Wavelength spokeswoman said by email. N,N-diethyl-4,5-dimethyl-6H-1,3-thiazin-2-amine vendor & factory The review considered two cases of AML in patients treated with an investigational medicine, bb1111, in a clinical trial for sickle cell disease. Although there have been no reports of AML with Zynteglo, both medicines use the same viral vector and there was a concern that the vector may be implicated in the development of the cancer (insertional oncogenesis).,The ability of a CDMO to lay down good quality audits, knowledge of equipment, packaging configurations, and good capability building of resources, helps in determining a competent CDMO partner.